Pioneering studies developed PROTACs like MD-222 and MD-224, which recruit cereblon E3 ligase to facilitate MDM2 degradation, significantly enhancing anti-tumor activity compared to conventional inhibitors (Li et al., 2019). Here, MDM2 is linked to neoplasm.